

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10506592	
	Filing Date		2004-09-03	
	First Named Inventor	Andrew Morley		
	Art Unit	1626		
	Examiner Name	NOLAN, JASON MICHAEL		
	Attorney Docket Number	100659-1P US		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040266768		2004-12-30	Schoenafinger et al.	
	2	20040142938		2004-07-22	Sher et al.	
	3	20040220229		2004-11-04	Bussolotti et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	2004113345	WO	A1	2004-12-29	Japan Tobacco Inc.		<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10506592
Filing Date		2004-09-03
First Named Inventor	Andrew Morley	
Art Unit	1626	
Examiner Name	NOLAN, JASON MICHAEL	
Attorney Docket Number	100659-1P US	

2	03/045920	WO	A1	2003-06-05	Merck & Co., Inc.		<input type="checkbox"/>
3	03/072570	WO	A1	2003-09-04	Pfizer Products Inc.		<input type="checkbox"/>
4	1 340 500	EP	A1	2003-09-03	Pfizer Products Inc.		<input type="checkbox"/>
5	2004/041780	WO	A2	2004-05-21	Pfizer Products Inc.		<input type="checkbox"/>
6	2004/092158	WO	A1	2004-10-28	Pfizer Products Inc.		<input type="checkbox"/>
7	1 338 594	EP	A1	2003-08-27	Shionogi & Co., Ltd.		<input type="checkbox"/>
8	03/091213	WO	A1	2003-11-06	Yamanouchi Pharmaceutical Co., Ltd.		<input checked="" type="checkbox"/>
9	2004196702	JP	A	2004-07-15	Yamanouchi Pharmaceutical Co., Ltd.		<input checked="" type="checkbox"/>
10	2005/013981	WO	A1	2005-02-17	AstraZeneca AB		<input type="checkbox"/>
11	2005/013975	WO	A1	2005-02-17	AstraZeneca AB		<input type="checkbox"/>
12	2005/020986	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10506592
Filing Date		2004-09-03
First Named Inventor	Andrew Morley	
Art Unit	1626	
Examiner Name	NOLAN, JASON MICHAEL	
Attorney Docket Number	100659-1P US	

13	2005/020985	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
14	2005/019172	WO	A1	2005-03-03	AstraZeneca AB		<input type="checkbox"/>
15	2005/018637	WO	A1	2005-03-03	AstraZeneca AB		<input type="checkbox"/>
16	2005/020987	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
17	2001247565	JP	A	2001-09-11	Pfizer Prod Inc		<input checked="" type="checkbox"/>
18	01/32622	WO	A1	2001-05-10	AstraZeneca AB		<input type="checkbox"/>
19	02/20530	WO	A1	2002-03-14	AstraZeneca AB		<input type="checkbox"/>
20	03/074517	WO	A1	2003-09-12	AstraZeneca AB		<input type="checkbox"/>
21	03/074484	WO	A1	2003-09-12	AstraZeneca AB		<input type="checkbox"/>
22	03/074532	WO	A1	2003-09-12	AstraZeneca AB		<input type="checkbox"/>
23	03/074531	WO	A1	2003-09-12	AstraZeneca AB		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10506592	
	Filing Date		2004-09-03	
	First Named Inventor	Andrew Morley		
	Art Unit	1626		
	Examiner Name	NOLAN, JASON MICHAEL		
	Attorney Docket Number	100659-1P US		

24	03/074513	WO	A2	2003-09-12	AstraZeneca AB		<input type="checkbox"/>
25	2004/031193	WO	A1	2004-04-15	AstraZeneca AB		<input type="checkbox"/>
26	2004/031194	WO	A1	2004-04-15	AstraZeneca AB		<input type="checkbox"/>
27	2004/104001	WO	A2	2004-12-02	OSI Pharmaceuticals Inc		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Crochet, R.A., et al., J. Het. Chem., "Synthesis of Substituted Thieno[2,3-b] pyrroles," Vol. 11, 143-150 (April 1974).	<input type="checkbox"/>
	2	Vertigan, H., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," Diabetologia, 47, Supp.1, 589, A214 (2004)	<input type="checkbox"/>
	3	Teague, J., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," Diabetes, 52, Supp. 2, A365, 1521-P (2003)	<input type="checkbox"/>
	4	Font, M. et al. "Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase", European Journal Med Chem (1995), 30(12), 963-71	<input type="checkbox"/>
	5	Vertigan, H. et al. "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents", EASD Munich (2004)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10506592
Filing Date		2004-09-03
First Named Inventor	Andrew Morley	
Art Unit	1626	
Examiner Name	NOLAN, JASON MICHAEL	
Attorney Docket Number	100659-1P US	

6	Bartlett, J. et al. "In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase", ADA San Diego (2005)	<input type="checkbox"/>
7	Green, A R. et al. "The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation", J Biol Chem, 279(45), 46474-46482 (2004)	<input type="checkbox"/>
8	Roberts, P A. et al. " The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle", J Physiology-London 545(1), 297-304 (2002)	<input type="checkbox"/>
9	Simpson, I. et al. "Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase", Cambridge Med Chem Conference, (Sept 2005). Poster EOM	<input type="checkbox"/>
10	Birch, A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, Cambridge Med Chem Symposium (Sept 2003)	<input type="checkbox"/>
11	Freeman, S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 1470-P, A340 (2003)	<input type="checkbox"/>
12	Turnbull, A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 1485-P, A343 (2003)	<input type="checkbox"/>
13	Lin, T. et al. "Effects of Protein Binding and Experimental Disease States on Brain Uptake of Benzodiazepines in Rats", J Pharmacology & Eptl Therapeutics (1990), 253(1), 45-50	<input type="checkbox"/>
14	Varnavas, A. et al. "Quinolone Derivatives: Synthesis and Binding Evaluation on Cholecystokinin Receptors", Farmaco (1996), 51(5), 341-350	<input type="checkbox"/>
15	Parsons, W H. et al. "Cholecystokinin Antagonists. Synthesis and Biological Evaluation of 3-Substitued Benzolactams", J Med Chem (1989), 32(8), 1681-5	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Add

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10506592
Filing Date	2004-09-03
First Named Inventor	Andrew Morley
Art Unit	1626
Examiner Name	NOLAN, JASON MICHAEL
Attorney Docket Number	100659-1P US

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10506592
Filing Date	2004-09-03
First Named Inventor	Andrew Morley
Art Unit	1626
Examiner Name	NOLAN, JASON MICHAEL
Attorney Docket Number	100659-1P US

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lucy Padget/	Date (YYYY-MM-DD)	2006-04-14
Name/Print	Lucy Padget Registration No.: L0074	Registration Number	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.